Theradiag Financials
| ALTHE Stock | EUR 0.26 0.01 3.70% |
Theradiag |
Understanding current and past Theradiag Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Theradiag's financial statements are interrelated, with each one affecting the others. For example, an increase in Theradiag's assets may result in an increase in income on the income statement.
Theradiag Stock Summary
Theradiag competes with Sensorion, Adocia, Spineguard, and Poxel SA. Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners. The company was founded in 2004 and is based in Malakoff, France. THERACLION operates under Medical Devices classification in France and is traded on Paris Stock Exchange. It employs 22 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0004197747 |
| Business Address | 102 Rue Etienne |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.theraclion.com |
| Phone | 33 1 55 48 90 70 |
| Currency | EUR - Euro |
You should never invest in Theradiag without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Theradiag Stock, because this is throwing your money away. Analyzing the key information contained in Theradiag's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Theradiag Key Financial Ratios
Theradiag's financial ratios allow both analysts and investors to convert raw data from Theradiag's financial statements into concise, actionable information that can be used to evaluate the performance of Theradiag over time and compare it to other companies across industries.Theradiag Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Theradiag's current stock value. Our valuation model uses many indicators to compare Theradiag value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Theradiag competition to find correlations between indicators driving Theradiag's intrinsic value. More Info.Theradiag SA is rated fourth in return on asset category among its peers. It also is rated fourth in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Theradiag's earnings, one of the primary drivers of an investment's value.Theradiag SA Systematic Risk
Theradiag's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Theradiag volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Theradiag SA correlated with the market. If Beta is less than 0 Theradiag generally moves in the opposite direction as compared to the market. If Theradiag Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Theradiag SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Theradiag is generally in the same direction as the market. If Beta > 1 Theradiag moves generally in the same direction as, but more than the movement of the benchmark.
Theradiag January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Theradiag help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Theradiag SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Theradiag SA based on widely used predictive technical indicators. In general, we focus on analyzing Theradiag Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Theradiag's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 28.97 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 9.68 |
Additional Tools for Theradiag Stock Analysis
When running Theradiag's price analysis, check to measure Theradiag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theradiag is operating at the current time. Most of Theradiag's value examination focuses on studying past and present price action to predict the probability of Theradiag's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theradiag's price. Additionally, you may evaluate how the addition of Theradiag to your portfolios can decrease your overall portfolio volatility.